MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Recommendation of “Hold” from Brokerages

MaxCyte, Inc. (NASDAQ:MXCT) has received an average recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $5.50.

A number of research analysts have recently commented on MXCT shares. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Finally, Craig Hallum lowered their price objective on MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th.

Institutional Investors Weigh In On MaxCyte

Several hedge funds have recently bought and sold shares of the business. Mirabella Financial Services LLP increased its stake in shares of MaxCyte by 78.4% during the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company’s stock valued at $14,388,000 after purchasing an additional 2,900,000 shares in the last quarter. Willis Investment Counsel boosted its position in shares of MaxCyte by 126.8% in the 3rd quarter. Willis Investment Counsel now owns 862,758 shares of the company’s stock worth $1,363,000 after purchasing an additional 482,287 shares in the last quarter. Kwmg LLC grew its stake in shares of MaxCyte by 75.8% in the 3rd quarter. Kwmg LLC now owns 25,833 shares of the company’s stock worth $41,000 after buying an additional 11,135 shares during the last quarter. Luminus Management LLC bought a new position in MaxCyte during the 3rd quarter valued at approximately $356,000. Finally, XTX Topco Ltd bought a new position in MaxCyte during the 2nd quarter valued at approximately $381,000. Institutional investors own 68.81% of the company’s stock.

MaxCyte Trading Up 0.7%

Shares of NASDAQ MXCT opened at $0.75 on Friday. The firm has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $1.29. MaxCyte has a 12 month low of $0.64 and a 12 month high of $2.96. The firm has a market capitalization of $80.10 million, a PE ratio of -1.74 and a beta of 1.23.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. MaxCyte had a negative net margin of 135.14% and a negative return on equity of 22.15%. The company had revenue of $6.76 million for the quarter, compared to analysts’ expectations of $9.16 million. On average, sell-side analysts predict that MaxCyte will post -0.42 earnings per share for the current year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.